TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02337010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CeVOX
Description: Central venous saturation was continuously monitored by using a CeVOX monitor (Pulsion Medical Systems, Munich, Germany). The CeVOX probe (PV2022-37; Pulsion Medical Systems, Munich, Germany) was inserted into the internal jugular central venous catheter as described in the user's manual.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CVP
Description: Central venous pressure was continuously monitored by using a central venous catheter. The probe was inserted into the internal jugular central vein as described in the user's manual.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluid bolus
Description: If hypovolaemia was suspected fluid bolus was given in the form of 250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluid bolus
Description: If hypovolaemia was suspected fluid bolus was given in the form of 250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressor
Description: If hypotension was present it was treated with vasopressor as 10 mcg bolus or continuous infusion of norepinephrine (Arterenol® Sanofi, Germany).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressor
Description: If hypotension was present it was treated with vasopressor as 10 mcg bolus or continuous infusion of norepinephrine (Arterenol® Sanofi, Germany).
Study: NCT01428063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study: NCT02142179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knowledge about Asthma and Respiratory Education (KARE)
Description: KARE - Knowledge about Asthma and Respiratory Education is an educational curriculum intervention organized with school staff to be applied to the intervention group. This intervention will consist of theoretical - practical weekly workshops with a targeted content for asthma and involves aspects related to anatomy and physiology of the respiratory tract, conceptualization of asthma, prevention, treatment, maintenance and retrieval; recognition and actions in periods of exacerbations and use the action plan. These workshops are suitable for the course plan of disciplines sciences, biology, chemistry, physics, history, geography, portuguese and mathematics. Those are characterized as a mandatory curriculum component and they should be developed for all students.
Study: NCT00920608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9056
Description: Tablets for oral use. 400 mg once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Tablet for oral use.7.5 to 20 mg single dose administration at visit 2 and 3.
Study: NCT04077970

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intrauterine flushing of follicular fluid with granulosa cells
Description: All patients in case and control groups will receive agonist and antagonist protocol. Ovarian stimulation will be carried out when pituitary desensitization is achieved and is continued until the day of hCG administration. COCs aspiration will be performed 34-36h after hCG injection. Clear Follicular Fluids (without blood cells) which contain COCs will be used. Endometrial flushing after oocyte retrieval with 2 ml of clear FF plus granulose cells will be performed by an IUI catheter. The control group included 70 women who would not have FF endometrial flushing. In both groups, embryo transfer will be carried out 2-3 days later. Luteal phase support will be started the day after ovum pick up by the vaginal administration of progesterone daily for 16 days and will continued for up to12 weeks if pregnancy occurred. Pregnancy was diagnosed by measurement of β-hCG level and later was confirmed by Transvaginal sonography.
Study: NCT02330627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Valence System Treatment
Description: Clinician-administered one-hour treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) between sessions.
Study: NCT03502252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semillas de Apego
Description: Group-based Primary Caregiver Intervention: Group-based psychosocial program for victimized mothers (or alternative primary caregivers) with children 2 to 5, that aims at promoting healthy child-parent attachments as a pathway for a proper development among children exposed to violence.
Study: NCT03899129

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simultaneous working length control using E-CONNECT S
Description: E-CONNECT S (Eighteeth medical technology Co., Ltd, china) is an endomotor with integrated apex locator newly introduced in the market with continuous WL measuring function. It contains an optional module for rotary instrumentation, allowing the device to function as a low-speed handpiece, apex locator, or a combination of both. This motor has an attention-grabbing property that when an instrument reaches the predetermined working length, the motor automatically stops the instrumentation. Thus, it can be concluded that automatically stopping instrumentation when the instrument reaches the working length would decrease postoperative pain compared with manually controlling the working length by using stoppers during instrumentation (separate length determination and root canal preparation).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: separate length determination and root canal preparation using Root ZX apex locator.
Description: Using manual control of the working length by using stoppers during instrumentation (separate length determination and root canal preparation) using Root ZX apex locator.
Study: NCT03161639

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulpectomies
Description: Primary teeth pulpectomy is an important treatment option for necrotic teeth. The correct working length will determine a better chemical and mechanical disinfection of the root canals, without demanding the surrounding periapical tissues and dental germs. In addition, it decreases the chance of a sub or over-filling, which also may interfere with the achievement of the success.
Study: NCT03657914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-hole inflatable mediastinal mirror
Description: The radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma is new minimally invasive operation for esophageal carcinoma. All enrolled subjects will receive this operation for their ESCC.
Study: NCT03397615

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Betadine douches
Description: subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery
Study: NCT02988466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haplo HCT <55 years old
Description: * Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel)~* Total body irradiation (TBI)~* Non-T-cell depleted donor bone marrow stem cell infusion Day 0

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haplo HCT ≥55 years old
Description: * Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel): Dose reduction by 30%~* Total body irradiation (TBI)~* Non-T-cell depleted donor bone marrow stem cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD Prophylaxis
Description: * Cyclophosphamide (Cy)~* Tacrolimus (Tac)~* Mycophenolate mofetil (MMF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD Prophylaxis
Description: * Cyclophosphamide (Cy)~* Tacrolimus (Tac)~* Mycophenolate mofetil (MMF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD Prophylaxis
Description: * Cyclophosphamide (Cy)~* Tacrolimus (Tac)~* Mycophenolate mofetil (MMF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD Prophylaxis
Description: * Cyclophosphamide (Cy)~* Tacrolimus (Tac)~* Mycophenolate mofetil (MMF)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haplo HCT ≥55 and < 65 years old
Description: * Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Melphalan (Mel)~* Total body irradiation (TBI)~* non-T-cell depleted donor bone marrow stem cells
Study: NCT01661283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10 mg/kg dose every 14 days
Study: NCT00784615

Intervention type: PROCEDURE
Intervention: Blood samples, transvaginal ultrasound
Description: Total testosterone, bioavailable testosterone, Free androgen index, Total cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, insulinemia, OGTT, HOMA index, Adiponectin, C Reactive Protein
Study: NCT02988466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haplo HCT ≥65 and ≤75 years old
Description: * Fludarabine (Flu)~* Cyclophosphamide (Cy)~* Total body irradiation (TBI)
Study: NCT03779425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Physical Therapy
Description: Participants will undergo a non-weight bearing knee range of motion virtual reality physical therapy session.
Study: NCT04539249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Description: 1g of paracetamol as an I.V infusion and 4g of magnesium sulphate as an I.V. bolus preoperatively. Continuous infusion of 1g/hr of magnesium sulphate intraoperatively and for the first 2 hours post-operatively. Further post-operatively, 100 mg of suppository diclofenac 12 hourly, intravenous paracetamol 1g 6 hourly, both over 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentazocine
Description: Post-operatively, suppository diclofenac 100mg 12 hourly, intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) 6 hourly, intravenous paracetamol 1g 6 hourly, all for 24 hours.~N.B: Intramuscular pentazocine 30 mg (45 mg if patient is \> 70 kg) will be used as rescue analgesia as needed (that is, only on patients' request for further analgesia or following an assessment of moderate to severe pain despite the planned analgesic regimen) at least 4 hourly during the first 24 hours after caesarean section.
Study: NCT04261634

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concentrated Growth Factor Membrane
Description: Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Concentrated Growth Factor Membrane
Description: Concentrated growth factor is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin
Description: Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Fibrin
Description: Platelet Rich Fibrinis produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
Study: NCT01313312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Dysport® was supplied to the study centres in vials containing 500 U of botulinum toxin type A (BTX-A). Depending on the dose administered up to 3 vials were required for the injection.~Each vial was reconstituted with sodium chloride for injection (0.9%). A total volume of 5.0 mL of the reconstituted product was injected for Dysport® 500 U and 1000 U, and 7.5 mL was injected for Dysport® 1500 U.
Study: NCT03993132

Intervention type: DRUG
Intervention: Empagliflozin
Description: new users (initiators) of Empagliflozin

Intervention type: DRUG
Intervention: Liraglutide
Description: initiators of Liraglutide
Study: NCT01034189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab: loading dose 400 mg/m2, 2h- IVF, 3\~ 5 days prior to starting CCRT (on week-1); followed by 250 mg/m2/ week, 1h- IVF, for 4 weeks (i.e., week 1 to week 4. during CCRT).
Study: NCT01260467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: 10 milligrams orally twice a day
Study: NCT01034189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: T: Paclitaxel 35 mg/m2, 1h IVF, on day 1 and day 4 of each week, week1 to week4 during CCRT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: P: Cisplatin 15 mg/m2, 1 h IVF, on day 2 and day 5 of each week, week1 to week4 during CCRT.
Study: NCT02488551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-delivered CALM
Description: This intervention includes the delivery of CALM via computer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual-delivered CALM
Description: This active comparison condition includes the delivery of CALM via manual
Study: NCT00524316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Transarterial chemoembolization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given Orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative Study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepatic artery embolization
Description: Surgical procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Correlative Study
Study: NCT00251407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
Study: NCT01034189

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy: (three-dimensional conformal radiotherapy or intensity modulated radiotherapy) 200 cGy/fraction, once daily, 5 days a week, to a total dose of 4000 cGy.
Study: NCT03414320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gathering data
Description: Gathering data about sleep, heart rate, carbohydrate intake, insulin pump, continuous glucose sensor, meals.
Study: NCT00671333

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LRTI
Description: Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, trapeziectomy using a cruciate osteotomy and rongeurs, creation of a metacarpal base bone tunnel using a high speed burr, harvesting of entire FCR tendon through two transverse volar incisions, ligament reconstruction and tendon interposition using Fibre Wire suture. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ascension PyroDisk
Description: Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, distal 2 mm of trapezium and dorsal cortex of both trapezium and metacarpal removed using osteotomes/rongeurs. A hole is drilled through the trapezium from dorsal to resected distal surface, and a second hole is drilled through the first metacarpal from the resected base to the dorsal surface. A slip of FCR is harvested. The tendon is woven through the trapezium, the central hole in the device, and the metacarpal tunnel then sutured back onto itself. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.
Study: NCT01769989

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrodermabrasion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabrasion
Study: NCT04203797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dupilumab
Description: Pre-filled syringe administered by subcutaneous (SC) injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Pre-filled syringe administered by subcutaneous (SC)
Study: NCT02433457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Omeprazole (OMP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Omeprazole (OMP)
Study: NCT00023946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02326051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy
Study: NCT01768143

Intervention type: BEHAVIORAL
Intervention: unexperienced endoscopy nurses

Intervention type: BEHAVIORAL
Intervention: Experienced endoscopy nurses
Study: NCT05280964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Better Together Physician Coaching
Description: 6 month, online group coaching program
Study: NCT00087269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic endoscopic surgery
Description: Undergo surgical resection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04311229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative-Pressure Wound Therapy group
Description: The wounds were initially evaluated for any necrotic findings and debrided if needed, and then washed with an antiseptic solution. 3-DWM was used to measure the pressure sores by taking pictures.The length and width of wounds were measured with disposable paper rulers. Wound depth was determined in centimeters with a sterile cotton-tip applicator by measuring against a ruler. The wound was closed using a Wound Care Kit that includes foam dressing, film drape, TRAC pad with tubing and a drainage canister. Foam material was placed inside the wound and was attached to the canister through tubing.The canister was attached to the Vacuum-Assisted Closure device, which is a portable device that applies intermittent or continuous negative pressure.The device was operated at 125 mmHg pressure for 5 minutes with and 2 minutes without active vacuum.Wound dressings were changed every 48 hours.Wound area was measured after all three rounds of treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: contol group
Description: Wounds were finally covered with gauze dressing soaked with saline. Wounds were treated three times a day, and measurements were repeated every 48 hours. Every wound was measured a total of four times: one pre-treatment (baseline) and three post-treatment measurements.
Study: NCT01714557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin
Description: 4.0g q8h 3-5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam combination product
Description: 4.5g q8h 3-5 days
Study: NCT00251407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11
Description: Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
Study: NCT00947570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for anxiety
Description: 10 sessions delivered over the course of 14 weeks and aimed at reducing pathological behaviors and patterns of thought
Study: NCT03531437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.5 mg estradiol and 2.5 mg nomegestrol acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15 µg ethinylestradiol and 60 µg gestodene
Study: NCT02491437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 30 mg
Description: Oral Dydrogesterone 10 mg tablets tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravaginal progesterone gel 90 mg
Study: NCT00782015

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Almonds
Description: 3 oz. of almonds per day, supplied as 1 oz. snack packs to be consumed for 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator:
Description: NCEP Step 2 diet
Study: NCT03152916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3d printing personalized plate
Description: 3d printing personalized plate will be used in the subtalar arthrodensis
Study: NCT02258009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg intravitreal injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg intravitreal injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: 2 mg intravitreal injections
Study: NCT03238586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WELL Program
Study: NCT02419183

Intervention type: OTHER
Intervention: SAMSTAR
Description: This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.